Clinical Trial Update: Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating docetaxel with or without the FGFR inhibitor AZD4547 in recurrent non-small cell lung cancer, including squamous cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• AZD4547
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-03-01